Metabolic Surgery May Be Beneficial in MASH-Related Cirrhosis, Obesity
By Elana Gotkine HealthDay Reporter
MONDAY, Feb. 3, 2025 -- For patients with compensated metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis and obesity, metabolic surgery is associated with a lower risk for incident major adverse liver outcomes (MALO), according to a study published online Jan. 27 in Nature Medicine.
Ali Aminian, M.D., from the Bariatric and Metabolic Institute at the Cleveland Clinic, and colleagues conducted an observational study to compare the effects of metabolic surgery and nonsurgical treatment in patients with obesity and compensated histologically proven MASH-related cirrhosis. The time-to-incident MALO was compared for 62 patients who underwent metabolic surgery and 106 nonsurgical controls who were followed for a mean of 10.0 ± 4.5 years.
The researchers found that the 15-year cumulative incidence of MALO was 20.9 and 46.4 percent in the surgical and nonsurgical groups, respectively, with an adjusted hazard ratio of 0.28. The 15-year cumulative incidence of decompensated cirrhosis was 15.6 and 30.7 percent in the surgical and nonsurgical groups, respectively (adjusted hazard ratio, 0.20).
"In the absence of approved medical therapies for compensated MASH-related cirrhosis, metabolic surgery may represent a safe and effective therapeutic option to influence the trajectory of cirrhosis in selected patients," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death
WEDNESDAY, May 28, 2025 -- For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related...
Post-Kidney Transplant Adverse Outcomes Increased With BMI-BSA Obesity
TUESDAY, May 27, 2025 -- Combined body mass index (BMI)-body surface area (BSA) obesity is associated with an increased risk for post-kidney transplant (KT) adverse outcomes...
Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss
FRIDAY, May 23, 2025 -- Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.